Shanghai Kaibao Pharmaceut (300039.SZ) traded flat 0 % during a 24 hours period ending at 06:40 AM Central Europe on Thursday 29th. One Shanghai Kaibao Pharmaceut stock can currently be bought for about CNY 4.74 on popular exchanges. Current supply of Shanghai Kaibao Pharmaceut stocks is 1 bn. Shanghai Kaibao Pharmaceut has a current market capitalization of CNY 5 bn and approximately CNY 38.9 mn worth of Shanghai Kaibao Pharmaceut was traded on exchanges in the last 24 hours. Since last month end, Shanghai Kaibao Pharmaceut has traded -6.8 % down. Simple moving average of last 200 days is at CNY 5.16. The highest price of past 52 weeks was recorded at CNY 6.77 on 02/06/2026. 52 weeks low was at CNY 4.02 on 06/29/2026.
Here is how related stocks have performed in the past 24 hours:
Hangzhou Youngsun Intellig (603901.SS) traded flat 0 % and now trades at CNY 10.38. Current market capitalisation for Hangzhou Youngsun Intellig is CNY 6 bn. Current price/earnings ratio for Hangzhou Youngsun Intellig is 26.36.
Xinya Electronic (605277.SS) traded flat 0 % and now trades at CNY 14.09. Current market capitalisation for Xinya Electronic is CNY 833.3 mn. Current price/earnings ratio for Xinya Electronic is 24.64.
Montnets Cloud (002123.SZ) traded flat 0 % and now trades at CNY 7.65. Montnets Cloud has a market capitalisation of CNY 6 bn.
Hubei Hongyuan Pharmaceuti (301246.SZ) traded flat 0 % and now trades at CNY 15.84. Current market capitalisation for Hubei Hongyuan Pharmaceuti is CNY 6 bn.
Cisen Pharmaceutical Lt (603367.SS) traded flat 0 % and now trades at CNY 13.07. Current market capitalisation for Cisen Pharmaceutical Lt is CNY 6 bn. Current price/earnings ratio for Cisen Pharmaceutical Lt is 13.1.
About Shanghai Kaibao Pharmaceut
Shanghai Kaibao Pharmaceutical Co Ltd. is a health care company operating in the pharmaceutical industry. The company, established in 2000 and headquartered in Shanghai, China, researches, develops, produces, and sells Chinese medicines primarily within China. Their main product is Tanreqing injection used for heat detoxification, cough and phlegm, pneumonia, acute and chronic bronchitis, and upper respiratory tract infection. Additionally, the company provides Tanreqing and Kaibao Chuanxiong capsules; and Kaibao sustained-release Kaibao Weiyun tablets. Apart from traditional Chinese medicines, the company also offers western medicines in various dosage forms, such as freeze-dried powder injections, small-capacity injections, tablets, capsules, granules, pills, creams, and other formulations. These include Kasilai, a freeze-dried powder injection; hiophening sodium and Shanhaidan products, Qizhi capsules, and spot bald pills; and Yuan Man health wine. The company’s website is www.xykb.com , and it is listed on the Shenzhen Stock Exchange. The IPO date for this company is 2010-01-08.